Overview

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with active, subfoveal choroidal neovascularization associated with neovascular Age-Related Macular Degeneration (AMD).
Phase:
Phase 1
Details
Lead Sponsor:
PanOptica, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions
Ranibizumab